Moderna’s mRNA cancer vaccine helped prevent relapse for melanoma patients, results from a mid-stage trial showed, demonstrating progress in the pursuit of shots to ward off cancer by jump-starting the immune system
Moderna Inc.’s cancer vaccine helped prevent relapse for melanoma patients, results from a midstage trial showed, demonstrating progress in the pursuit of shots to ward off cancer by jump-starting the immune system.
About 79% of high-risk melanoma patients who got Moderna’s personalized vaccine and Merck & Co.’s immunotherapy Keytruda were alive and cancer-free at 18 months, compared with about 62% of patients who received immunotherapy alone, researchers said Sunday. The 157-person trial offers some of the strongest evidence yet that such vaccines could benefit cancer patients.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
8 TV Shows That Really Did Not Need That Spin-Off, And 8 Shows That DidI want to know if you think we needed Gilmore Girls: A Year in the Life...
Consulte Mais informação »
JPMorgan Chase’s stock surges toward biggest 1-day, post-earnings gain in 15 yearsJPMorgan Chase & Co.’s stock jumped 7.1% in midday trading, enough to pace the S&P 500’s advancers, after the banking giant reported blowout first-quarter...
Consulte Mais informação »
British Army lurches toward electrificationBabcock International has been handed cash to explore EV propulsion in Army vehicles. Good luck with that ⚡️
Consulte Mais informação »
NZD/USD ends two-day gain streak and falls toward 0.6200NZD/USD snapped two days of consecutive gains and slid past the 200, 50, and 100-day Exponential Moving Averages (EMAs) on a risk-off impulse spurred
Consulte Mais informação »
As XFL playoffs slip from reach, San Antonio Brahmas keep eye toward NFL dreamsWith two games remaining in the season, the Brahmas need a pair of wins and two Arlington losses to force a tiebreaker for playoff position.
Consulte Mais informação »
Editorial: Prop A is bad policy masked as progressVoters would be wise to reject Proposition A, which is woefully off target.
Consulte Mais informação »